Steven R. Bauer
Research Subjects
Research Interests
Steven R. Bauer has a total of 259 co-authors. Here are the top co-authors by number of shared publications:
Fritz Melchers
Basel Institute for Immunology, Switzerland
4 shared publicationsJessica L. Lo Surdo
Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993
4 shared publicationsMatthew W. Klinker
Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA
4 shared publications- Ross A. Marklein
School of Chemical, Materials, and Biomedical Engineering, University of Georgia, Athens, USA
4 shared publications - Akira Kudo
Showa University
3 shared publications - Andreas Strasser
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia
3 shared publications
Latest Publications
- Open Access
- 30 August 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (9) , 938
A Collaborative Data Sharing Platform to Accelerate Translation of Biomedical Innovations
This perspective article presents an innovative concept for a biomanufacturing Knowledge Hub (KH), designed as a data-driven learning platform supporting the entire lifecycle of biomedical products. By integrating advanced data sharing and processing technologies, the KH aspires to connect patients, bioengineers, clinicians, regulators, companies, and investors to accelerate product development, reduce redundancies, and ultimately fast-track the delivery of biomedical innovations to patients. We discuss current challenges in accessing and sharing data within biomanufacturing and outline novel approaches for building an ecosystem that links data stores, integrates digital twins, and leverages advanced analytics. The KH offers transformative capabilities, enabling the development of new products at a substantial increased speed. It is built as a secure, quantum-resistant platform that encrypts data and allows access through advanced algorithms, creating an intelligent, collaborative environment. Users can harness collective knowledge to enhance products, launch innovations, integrate technologies, and unlock revenue opportunities based on data quality and usage. This KH aims to revolutionize biomanufacturing, offering unprecedented opportunities for innovation, better patient outcomes, and commercialization with far reaching applications beyond biomanufacturing in the future.
- 30 August 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (9) , 938
Open AccessA Collaborative Data Sharing Platform to Accelerate Translation of Biomedical Innovations
This perspective article presents an innovative concept for a biomanufacturing Knowledge Hub (KH), designed as a data-driven learning platform supporting the entire lifecycle of biomedical products. By integrating advanced data sharing and processing technologies, the KH aspires to connect patients, bioengineers, clinicians, regulators, companies, and investors to accelerate product development, reduce redundancies, and ultimately fast-track the delivery of biomedical innovations to patients. We discuss current challenges in accessing and sharing data within biomanufacturing and outline novel approaches for building an ecosystem that links data stores, integrates digital twins, and leverages advanced analytics. The KH offers transformative capabilities, enabling the development of new products at a substantial increased speed. It is built as a secure, quantum-resistant platform that encrypts data and allows access through advanced algorithms, creating an intelligent, collaborative environment. Users can harness collective knowledge to enhance products, launch innovations, integrate technologies, and unlock revenue opportunities based on data quality and usage. This KH aims to revolutionize biomanufacturing, offering unprecedented opportunities for innovation, better patient outcomes, and commercialization with far reaching applications beyond biomanufacturing in the future.
- Open Access
- 11 June 2025
- Published by Springer Nature in Current Stem Cell Reports
- Vol. 11 (1) , 1-12
Review of Disruptive Technologies in 3D Bioprinting
Purpose of Review: The purpose of this review is to share insights from recognized experts in 3D biopriniting on the recent advances in these technologies discussed during a recent workshop held in conjunction with the 2024 ISS National Laboratory Research and Development Conference (ISSRDC). We seek to answer how microgravity can be used as a disruptor to make further advances not possible through conventional means. Recent Findings: This review will cover current efforts underway to use microgravity for 3D bioprinting. For instance multi-levitation biofabrication technology funded under the EU PULSE project is currently being used to create cardiovascular 3D in vitro models to better mimic cardiac and vascular physiology compared to organoids. These types of models could be expanded to other organ systems and disease models to use the environment of microgravity to unlock new signaling pathways to cure disease. Summary: The major takeaway from this review is that microgravity will unlock new opportunities for 3D bioprinting that were simply not possible using conventional means. We provide forward looking answers to what microgravity will inspire from advanced biomaterials to new disease models to even creating a knowledge hub for 3D bioprinting to launch new platforms at record speeds.
- 11 June 2025
- Published by Springer Nature in Current Stem Cell Reports
- Vol. 11 (1) , 1-12
Open AccessReview of Disruptive Technologies in 3D Bioprinting
Purpose of Review: The purpose of this review is to share insights from recognized experts in 3D biopriniting on the recent advances in these technologies discussed during a recent workshop held in conjunction with the 2024 ISS National Laboratory Research and Development Conference (ISSRDC). We seek to answer how microgravity can be used as a disruptor to make further advances not possible through conventional means. Recent Findings: This review will cover current efforts underway to use microgravity for 3D bioprinting. For instance multi-levitation biofabrication technology funded under the EU PULSE project is currently being used to create cardiovascular 3D in vitro models to better mimic cardiac and vascular physiology compared to organoids. These types of models could be expanded to other organ systems and disease models to use the environment of microgravity to unlock new signaling pathways to cure disease. Summary: The major takeaway from this review is that microgravity will unlock new opportunities for 3D bioprinting that were simply not possible using conventional means. We provide forward looking answers to what microgravity will inspire from advanced biomaterials to new disease models to even creating a knowledge hub for 3D bioprinting to launch new platforms at record speeds.
- 22 January 2024
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 19 (1) , 27-45
Experimental and Computational Approach to Establish Fit-for-Purpose Cell Viability Assays
Aim: Cell viability assays are critical for cell-based products. Here, we demonstrate a combined experimental and computational approach to identify fit-for-purpose cell assays that can predict cha... Plain language summary In recent years, there has been a surge in the amount of cellular therapy products which have been engineered to treat patients with severe diseases. These cellular products ... Graphical abstract
- 22 January 2024
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 19 (1) , 27-45
Experimental and Computational Approach to Establish Fit-for-Purpose Cell Viability Assays
Aim: Cell viability assays are critical for cell-based products. Here, we demonstrate a combined experimental and computational approach to identify fit-for-purpose cell assays that can predict cha... Plain language summary In recent years, there has been a surge in the amount of cellular therapy products which have been engineered to treat patients with severe diseases. These cellular products ... Graphical abstract
- 30 October 2021
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 119 (2) , 361-375
Morphological landscapes from high content imaging reveal cytokine priming strategies that enhance mesenchymal stromal cell immunosuppression
Successful clinical translation of mesenchymal stromal cell (MSC) products has not been achieved in the United States and may be in large part due to MSC functional heterogeneity. Efforts have been made to identify “priming” conditions that produce MSCs with consistent immunomodulatory function; however, challenges remain with predicting and understanding how priming impacts MSC behavior. The purpose of this study was to develop a high throughput, image‐based approach to assess MSC morphology in response to combinatorial priming treatments and establish morphological profiling as an effective approach to screen the effect of manufacturing changes (i.e., priming) on MSC immunomodulation. We characterized the morphological response of multiple MSC lines/passages to an array of Interferon‐gamma (IFN‐γ) and tumor necrosis factor‐⍺ (TNF‐⍺) priming conditions, as well as the effects of priming on MSC modulation of activated T cells and MSC secretome. Although considerable functional heterogeneity, in terms of T‐cell suppression, was observed between different MSC lines and at different passages, this heterogeneity was significantly reduced with combined IFN‐γ/TNF‐⍺ priming. The magnitude of this change correlated strongly with multiple morphological features and was also reflected by MSC secretion of immunomodulatory factors, for example, PGE2, ICAM‐1, and CXCL16. Overall, this study further demonstrates the ability of priming to enhance MSC function, as well as the ability of morphology to better understand MSC heterogeneity and predict changes in function due to manufacturing.
- 30 October 2021
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 119 (2) , 361-375
Morphological landscapes from high content imaging reveal cytokine priming strategies that enhance mesenchymal stromal cell immunosuppression
Successful clinical translation of mesenchymal stromal cell (MSC) products has not been achieved in the United States and may be in large part due to MSC functional heterogeneity. Efforts have been made to identify “priming” conditions that produce MSCs with consistent immunomodulatory function; however, challenges remain with predicting and understanding how priming impacts MSC behavior. The purpose of this study was to develop a high throughput, image‐based approach to assess MSC morphology in response to combinatorial priming treatments and establish morphological profiling as an effective approach to screen the effect of manufacturing changes (i.e., priming) on MSC immunomodulation. We characterized the morphological response of multiple MSC lines/passages to an array of Interferon‐gamma (IFN‐γ) and tumor necrosis factor‐⍺ (TNF‐⍺) priming conditions, as well as the effects of priming on MSC modulation of activated T cells and MSC secretome. Although considerable functional heterogeneity, in terms of T‐cell suppression, was observed between different MSC lines and at different passages, this heterogeneity was significantly reduced with combined IFN‐γ/TNF‐⍺ priming. The magnitude of this change correlated strongly with multiple morphological features and was also reflected by MSC secretion of immunomodulatory factors, for example, PGE2, ICAM‐1, and CXCL16. Overall, this study further demonstrates the ability of priming to enhance MSC function, as well as the ability of morphology to better understand MSC heterogeneity and predict changes in function due to manufacturing.
- Open Access
Morphological Landscapes from High Content Imaging Identify Optimal Priming Strategies that Enhance MSC Immunosuppression
Successful clinical translation of mesenchymal stromal cell (MSC) products has not been achieved in the United States and may be in large part due to MSC functional heterogeneity. Efforts have been made to identify ‘priming’ conditions that produce MSCs with consistent immunomodulatory function; however, challenges remain with predicting and understanding how priming impacts MSC behavior. The purpose of this study was to develop a high throughput, image-based approach to assess MSC morphology in response to combinatorial priming treatments and establish morphological profiling as an effective approach to screen the effect of manufacturing changes (i.e. priming) on MSC immunomodulation. We characterized the morphological response of multiple MSC lines/passages to an array of Interferon-gamma (IFN-γ) and Tumor Necrosis Factor alpha (TNF-α) priming conditions, as well as the effects of priming on MSC modulation of activated T cells and MSC secretome. Although considerable functional heterogeneity, in terms of T cell suppression, was observed between different MSC lines and at different passages, this heterogeneity was significantly reduced with combined IFN-γ/TNF-α priming. The magnitude of this change correlated strongly with multiple morphological features and was also reflected by MSC secretion of immunomodulatory factors e.g. PGE2, ICAM-1, and CXCL16. Overall, this study further demonstrates the ability of priming to enhance MSC function, as well as the ability of morphology to better understand MSC heterogeneity and predict changes in function due to manufacturing.
Open AccessMorphological Landscapes from High Content Imaging Identify Optimal Priming Strategies that Enhance MSC Immunosuppression
Successful clinical translation of mesenchymal stromal cell (MSC) products has not been achieved in the United States and may be in large part due to MSC functional heterogeneity. Efforts have been made to identify ‘priming’ conditions that produce MSCs with consistent immunomodulatory function; however, challenges remain with predicting and understanding how priming impacts MSC behavior. The purpose of this study was to develop a high throughput, image-based approach to assess MSC morphology in response to combinatorial priming treatments and establish morphological profiling as an effective approach to screen the effect of manufacturing changes (i.e. priming) on MSC immunomodulation. We characterized the morphological response of multiple MSC lines/passages to an array of Interferon-gamma (IFN-γ) and Tumor Necrosis Factor alpha (TNF-α) priming conditions, as well as the effects of priming on MSC modulation of activated T cells and MSC secretome. Although considerable functional heterogeneity, in terms of T cell suppression, was observed between different MSC lines and at different passages, this heterogeneity was significantly reduced with combined IFN-γ/TNF-α priming. The magnitude of this change correlated strongly with multiple morphological features and was also reflected by MSC secretion of immunomodulatory factors e.g. PGE2, ICAM-1, and CXCL16. Overall, this study further demonstrates the ability of priming to enhance MSC function, as well as the ability of morphology to better understand MSC heterogeneity and predict changes in function due to manufacturing.
- Open Access
- 1 January 2019
- Published by Elsevier in Cytotherapy
- Vol. 21 (1) , 17-31
Morphological profiling using machine learning reveals emergent subpopulations of interferon-γ–stimulated mesenchymal stromal cells that predict immunosuppression
- 1 January 2019
- Published by Elsevier in Cytotherapy
- Vol. 21 (1) , 17-31
Open AccessMorphological profiling using machine learning reveals emergent subpopulations of interferon-γ–stimulated mesenchymal stromal cells that predict immunosuppression
- 1 January 2018
- Published by Elsevier in Trends in Biotechnology
- Vol. 36 (1) , 105-118
Functionally-Relevant Morphological Profiling: A Tool to Assess Cellular Heterogeneity
- 1 January 2018
- Published by Elsevier in Trends in Biotechnology
- Vol. 36 (1) , 105-118
Functionally-Relevant Morphological Profiling: A Tool to Assess Cellular Heterogeneity
- 10 March 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (13) , E2598-E2607
Morphological features of IFN-γ–stimulated mesenchymal stromal cells predict overall immunosuppressive capacity
Significance: Substantial evidence exists demonstrating the immunosuppressive function of mesenchymal stromal cells (MSCs), but inconsistent clinical results suggest that better understanding of MSC-mediated immunosuppression and identification of features predictive of immunosuppressive capacity would advance MSC-based therapeutics. In this work, we present a robust analytical approach to quantify the immunosuppressive capacity of MSCs by integrating high-dimensional flow cytometry data from multiple experimental conditions into a single measure of immunosuppressive capacity. Additionally, we identified morphological features of MSCs that predicted immunosuppressive capacity, as well as the magnitude of IFN-γ–mediated immunosuppression enhancement. These improved methods of MSC characterization could be used to identify MSC preparations with desired immunosuppressive capacity, as well as screen for pretreatments that enhance their immunosuppressive function.
- 10 March 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (13) , E2598-E2607
Morphological features of IFN-γ–stimulated mesenchymal stromal cells predict overall immunosuppressive capacity
Significance: Substantial evidence exists demonstrating the immunosuppressive function of mesenchymal stromal cells (MSCs), but inconsistent clinical results suggest that better understanding of MSC-mediated immunosuppression and identification of features predictive of immunosuppressive capacity would advance MSC-based therapeutics. In this work, we present a robust analytical approach to quantify the immunosuppressive capacity of MSCs by integrating high-dimensional flow cytometry data from multiple experimental conditions into a single measure of immunosuppressive capacity. Additionally, we identified morphological features of MSCs that predicted immunosuppressive capacity, as well as the magnitude of IFN-γ–mediated immunosuppression enhancement. These improved methods of MSC characterization could be used to identify MSC preparations with desired immunosuppressive capacity, as well as screen for pretreatments that enhance their immunosuppressive function.
- 1 April 2016
- Published by SAGE Publications in Stem Cells and Development
- Vol. 25 (11) , 861-873
Identification of Predictive Gene Markers for Multipotent Stromal Cell Proliferation
Multipotent stromal cells (MSCs) are known for their distinctive ability to differentiate into different cell lineages, such as adipocytes, chondrocytes, and osteocytes. They can be isolated from numerous tissue sources, including bone marrow, adipose tissue, skeletal muscle, and others. Because of their differentiation potential and secretion of growth factors, MSCs are believed to have an inherent quality of regeneration and immune suppression. Cellular expansion is necessary to obtain sufficient numbers for use; however, MSCs exhibit a reduced capacity for proliferation and differentiation after several rounds of passaging. In this study, gene markers of MSC proliferation were identified and evaluated for their ability to predict proliferative quality. Microarray data of human bone marrow-derived MSCs were correlated with two proliferation assays. A collection of 24 genes were observed to significantly correlate with both proliferation assays (| r | >0.70) for eight MSC lines at multiple passages. These 24 identified genes were then confirmed using an additional set of MSCs from eight new donors using reverse transcription quantitative polymerase chain reaction (RT-qPCR). The proliferative potential of the second set of MSCs was measured for each donor/passage for confluency fraction, fraction of EdU+ cells, and population doubling time. The second set of MSCs exhibited a greater proliferative potential at passage 4 in comparison to passage 8, which was distinguishable by 15 genes; however, only seven of the genes ( BIRC5, CCNA2, CDC20, CDK1, PBK, PLK1 , and SPC25 ) demonstrated significant correlation with MSC proliferation regardless of passage. Our analyses revealed that correlation between gene expression and proliferation was consistently reduced with the inclusion of non-MSC cell lines; therefore, this set of seven genes may be more strongly associated with MSC proliferative quality. Our results pave the way to determine the quality of an MSC population for a particular cellular therapy in lieu of an extended in vitro or in vivo assay.
- 1 April 2016
- Published by SAGE Publications in Stem Cells and Development
- Vol. 25 (11) , 861-873
Identification of Predictive Gene Markers for Multipotent Stromal Cell Proliferation
Multipotent stromal cells (MSCs) are known for their distinctive ability to differentiate into different cell lineages, such as adipocytes, chondrocytes, and osteocytes. They can be isolated from numerous tissue sources, including bone marrow, adipose tissue, skeletal muscle, and others. Because of their differentiation potential and secretion of growth factors, MSCs are believed to have an inherent quality of regeneration and immune suppression. Cellular expansion is necessary to obtain sufficient numbers for use; however, MSCs exhibit a reduced capacity for proliferation and differentiation after several rounds of passaging. In this study, gene markers of MSC proliferation were identified and evaluated for their ability to predict proliferative quality. Microarray data of human bone marrow-derived MSCs were correlated with two proliferation assays. A collection of 24 genes were observed to significantly correlate with both proliferation assays (| r | >0.70) for eight MSC lines at multiple passages. These 24 identified genes were then confirmed using an additional set of MSCs from eight new donors using reverse transcription quantitative polymerase chain reaction (RT-qPCR). The proliferative potential of the second set of MSCs was measured for each donor/passage for confluency fraction, fraction of EdU+ cells, and population doubling time. The second set of MSCs exhibited a greater proliferative potential at passage 4 in comparison to passage 8, which was distinguishable by 15 genes; however, only seven of the genes ( BIRC5, CCNA2, CDC20, CDK1, PBK, PLK1 , and SPC25 ) demonstrated significant correlation with MSC proliferation regardless of passage. Our analyses revealed that correlation between gene expression and proliferation was consistently reduced with the inclusion of non-MSC cell lines; therefore, this set of seven genes may be more strongly associated with MSC proliferative quality. Our results pave the way to determine the quality of an MSC population for a particular cellular therapy in lieu of an extended in vitro or in vivo assay.
- Open Access
- 11 February 2016
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 34 (4) , 935-947
High Content Imaging of Early Morphological Signatures Predicts Long Term Mineralization Capacity of Human Mesenchymal Stem Cells upon Osteogenic Induction
Human bone marrow-derived multipotent mesenchymal stromal cells, often referred to as mesenchymal stem cells (MSCs), represent an attractive cell source for many regenerative medicine applications due to their potential for multi-lineage differentiation, immunomodulation, and paracrine factor secretion. A major complication for current MSC-based therapies is the lack of well-defined characterization methods that can robustly predict how they will perform in a particular in vitro or in vivo setting. Significant advances have been made with identifying molecular markers of MSC quality and potency using multivariate genomic and proteomic approaches, and more recently with advanced techniques incorporating high content imaging to assess high-dimensional single cell morphological data. We sought to expand upon current methods of high dimensional morphological analysis by investigating whether short term cell and nuclear morphological profiles of MSCs from multiple donors (at multiple passages) correlated with long term mineralization upon osteogenic induction. Using the combined power of automated high content imaging followed by automated image analysis, we demonstrated that MSC morphology after 3 days was highly correlated with 35 day mineralization and comparable to other methods of MSC osteogenesis assessment (such as alkaline phosphatase activity). We then expanded on this initial morphological characterization and identified morphological features that were highly predictive of mineralization capacities (>90% accuracy) of MSCs from additional donors and different manufacturing techniques using linear discriminant analysis. Together, this work thoroughly demonstrates the predictive power of MSC morphology for mineralization capacity and motivates further studies into MSC morphology as a predictive marker for additional in vitro and in vivo responses. Stem Cells 2016;34:935–947
- 11 February 2016
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 34 (4) , 935-947
Open AccessHigh Content Imaging of Early Morphological Signatures Predicts Long Term Mineralization Capacity of Human Mesenchymal Stem Cells upon Osteogenic Induction
Human bone marrow-derived multipotent mesenchymal stromal cells, often referred to as mesenchymal stem cells (MSCs), represent an attractive cell source for many regenerative medicine applications due to their potential for multi-lineage differentiation, immunomodulation, and paracrine factor secretion. A major complication for current MSC-based therapies is the lack of well-defined characterization methods that can robustly predict how they will perform in a particular in vitro or in vivo setting. Significant advances have been made with identifying molecular markers of MSC quality and potency using multivariate genomic and proteomic approaches, and more recently with advanced techniques incorporating high content imaging to assess high-dimensional single cell morphological data. We sought to expand upon current methods of high dimensional morphological analysis by investigating whether short term cell and nuclear morphological profiles of MSCs from multiple donors (at multiple passages) correlated with long term mineralization upon osteogenic induction. Using the combined power of automated high content imaging followed by automated image analysis, we demonstrated that MSC morphology after 3 days was highly correlated with 35 day mineralization and comparable to other methods of MSC osteogenesis assessment (such as alkaline phosphatase activity). We then expanded on this initial morphological characterization and identified morphological features that were highly predictive of mineralization capacities (>90% accuracy) of MSCs from additional donors and different manufacturing techniques using linear discriminant analysis. Together, this work thoroughly demonstrates the predictive power of MSC morphology for mineralization capacity and motivates further studies into MSC morphology as a predictive marker for additional in vitro and in vivo responses. Stem Cells 2016;34:935–947